Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in prostatic glandular cells | 0.75 |
| chemistry Open Targets | compounds already reach it: difelikefalin, dezocine, hydrocodone bitartrate +34 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 5 Parkinson's papers of 238 | 0.76 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3418
Sealed predictions
- OPRK1 in dopamine neurons, braak+0.00 (p 1.000) → +0.47 (p 0.197)receipt 3426
Swarm cases
receipt 3426: OPRK1 in dopamine neurons, braak
- power
- full sample +0.21 (p 0.403, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.21 (p 0.403, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.21 (p 0.403, n 18). could be the mix.
- skeptic
- leave-one-out range +0.10 to +0.36, sign flips 0; without severely affected donors +0.21 (p 0.403, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for OPRK1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts